The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14–skipping+ NSCLC.
 
Rajaa Mohamed Salih
No Relationships to Disclose
 
Julia Berg
Employment - Bristol-Myers Squibb/Celgene (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene (I)
 
Page Widick
No Relationships to Disclose
 
Deepa Rangachari
Consulting or Advisory Role - Teladoc
Research Funding - Abbvie/Stemcentrx (Inst); Bristol-Myers Squibb (Inst); Novocure (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Paul Hesketh
Consulting or Advisory Role - UpToDate
 
Karl D'Silva
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene/Juno; Merck; Nuvation Bio; Verastem
Honoraria - Astellas Pharma; Jazz Pharmaceuticals; Pfizer; Pfizer
 
Daniel Costa
Honoraria - Pfizer; Takeda/Millennium
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Included Health; Janssen Oncology; Takeda/Millennium; Teladoc
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Merck (Inst); Merrimack (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); Takeda/Millennium (Inst)
 
AJ Piper-Vallillo
Consulting or Advisory Role - Takeda